Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HCM NASDAQ:IMVT NYSE:OGN NASDAQ:SANA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHCMHUTCHMED$17.54-2.2%$16.46$11.51▼$21.50$3.06B0.4579,836 shs47,251 shsIMVTImmunovant$15.53-3.9%$16.29$12.72▼$32.10$2.71B0.451.48 million shs2.15 million shsOGNOrganon & Co.$10.39-2.5%$9.64$8.01▼$21.06$2.70B0.64.40 million shs3.89 million shsSANASana Biotechnology$3.23+0.3%$3.72$1.26▼$7.30$768.13M1.885.76 million shs4.54 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHCMHUTCHMED0.00%+12.27%+9.00%+6.79%+3.70%IMVTImmunovant0.00%-5.72%+6.18%+4.33%-45.53%OGNOrganon & Co.0.00%+2.75%+12.94%+4.38%-47.97%SANASana Biotechnology0.00%+8.78%-3.30%+27.78%-27.96%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHCMHUTCHMED$17.54-2.2%$16.46$11.51▼$21.50$3.06B0.4579,836 shs47,251 shsIMVTImmunovant$15.53-3.9%$16.29$12.72▼$32.10$2.71B0.451.48 million shs2.15 million shsOGNOrganon & Co.$10.39-2.5%$9.64$8.01▼$21.06$2.70B0.64.40 million shs3.89 million shsSANASana Biotechnology$3.23+0.3%$3.72$1.26▼$7.30$768.13M1.885.76 million shs4.54 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHCMHUTCHMED0.00%+12.27%+9.00%+6.79%+3.70%IMVTImmunovant0.00%-5.72%+6.18%+4.33%-45.53%OGNOrganon & Co.0.00%+2.75%+12.94%+4.38%-47.97%SANASana Biotechnology0.00%+8.78%-3.30%+27.78%-27.96%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHCMHUTCHMED 2.33Hold$28.0059.64% UpsideIMVTImmunovant 2.83Moderate Buy$33.60116.36% UpsideOGNOrganon & Co. 2.80Moderate Buy$17.3366.91% UpsideSANASana Biotechnology 3.00Buy$8.00147.68% UpsideCurrent Analyst Ratings BreakdownLatest SANA, IMVT, HCM, and OGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/9/2025HCMHUTCHMEDZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold9/4/2025IMVTImmunovantHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$35.008/12/2025IMVTImmunovantJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$40.00 ➝ $37.008/12/2025IMVTImmunovantBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$33.00 ➝ $30.008/11/2025IMVTImmunovantCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy8/11/2025HCMHUTCHMEDZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy7/28/2025IMVTImmunovantUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$17.00 ➝ $18.007/22/2025HCMHUTCHMEDBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$27.00 ➝ $28.007/10/2025IMVTImmunovantThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold$18.007/3/2025SANASana BiotechnologyMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$12.006/24/2025SANASana BiotechnologyJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$5.00(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHCMHUTCHMED$602.20M5.08$0.28 per share62.42$4.43 per share3.96IMVTImmunovantN/AN/AN/AN/A$4.16 per shareN/AOGNOrganon & Co.$6.40B0.42$4.81 per share2.16$1.83 per share5.67SANASana BiotechnologyN/AN/AN/AN/A$1.12 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHCMHUTCHMED$37.73MN/A0.0012.01N/AN/AN/AN/AN/AIMVTImmunovant-$413.84M-$2.85N/AN/AN/AN/A-80.99%-72.23%11/6/2025 (Estimated)OGNOrganon & Co.$864M$2.693.862.780.9711.15%163.88%6.99%10/30/2025 (Estimated)SANASana Biotechnology-$266.76M-$1.06N/AN/AN/AN/A-91.96%-43.07%11/14/2025 (Estimated)Latest SANA, IMVT, HCM, and OGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q1 2026IMVTImmunovant-$0.69-$0.60+$0.09-$0.71N/AN/A8/11/2025Q2 2025SANASana Biotechnology-$0.20-$0.16+$0.04-$0.39N/AN/A8/5/2025Q2 2025OGNOrganon & Co.$0.94$1.00+$0.06$0.56$1.55 billion$1.59 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHCMHUTCHMEDN/AN/AN/AN/AN/AIMVTImmunovantN/AN/AN/AN/AN/AOGNOrganon & Co.$0.080.77%N/A2.97%N/ASANASana BiotechnologyN/AN/AN/AN/AN/ALatest SANA, IMVT, HCM, and OGN DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date8/5/2025OGNOrganon & Co.quarterly$0.020.9%8/15/20258/15/20259/11/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHCMHUTCHMED0.054.654.51IMVTImmunovantN/A12.3212.32OGNOrganon & Co.11.981.651.13SANASana BiotechnologyN/A2.472.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHCMHUTCHMED8.82%IMVTImmunovant47.08%OGNOrganon & Co.77.43%SANASana Biotechnology88.23%Insider OwnershipCompanyInsider OwnershipHCMHUTCHMED3.60%IMVTImmunovant1.80%OGNOrganon & Co.1.40%SANASana Biotechnology31.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHCMHUTCHMED1,811174.42 million168.14 millionNot OptionableIMVTImmunovant120174.32 million171.18 millionOptionableOGNOrganon & Co.4,000259.97 million256.33 millionNot OptionableSANASana Biotechnology380237.81 million163.85 millionOptionableSANA, IMVT, HCM, and OGN HeadlinesRecent News About These CompaniesSCS Capital Management LLC Takes $137,000 Position in Sana Biotechnology, Inc. $SANASeptember 15 at 4:07 AM | marketbeat.comSana Biotechnology (NASDAQ:SANA) Trading Down 6% - Here's What HappenedSeptember 14 at 3:39 PM | marketbeat.comSana Biotechnology (NASDAQ:SANA) Trading Up 10.1% - Still a Buy?September 13 at 4:20 PM | marketbeat.comCrispr Offers New Hope for Treating DiabetesSeptember 12 at 4:38 AM | wired.comWClearline Capital LP Takes Position in Sana Biotechnology, Inc. $SANASeptember 10, 2025 | marketbeat.comIeq Capital LLC Has $176,000 Position in Sana Biotechnology, Inc. $SANASeptember 9, 2025 | marketbeat.comInvesco Ltd. Purchases 117,144 Shares of Sana Biotechnology, Inc. $SANASeptember 9, 2025 | marketbeat.comSana Biotechnology, Inc. (SANA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 8, 2025 | seekingalpha.comJMP Securities Keeps Market Outperform Rating on Sana Biotechnology (SANA)September 8, 2025 | insidermonkey.comBrokerages Set Sana Biotechnology, Inc. (NASDAQ:SANA) Price Target at $8.00September 8, 2025 | americanbankingnews.comTop 10 Stocks Under $10 That Could TripleSeptember 7, 2025 | insidermonkey.comSana Biotechnology, Inc. (NASDAQ:SANA) Given Average Rating of "Buy" by AnalystsSeptember 7, 2025 | marketbeat.comHope for diabetes: CRISPR-edited cells pump out insulin in a person – and evade immune detectionSeptember 6, 2025 | nature.comNRafferty Asset Management LLC Has $328,000 Position in Sana Biotechnology, Inc. $SANASeptember 6, 2025 | marketbeat.com350,539 Shares in Sana Biotechnology, Inc. $SANA Bought by Nuveen LLCSeptember 6, 2025 | marketbeat.comSana Biotechnology, Inc. (SANA) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 TranscriptSeptember 5, 2025 | seekingalpha.comSana Biotechnology, Inc. $SANA Shares Sold by Baker BROS. Advisors LPSeptember 4, 2025 | marketbeat.comSana Biotechnology, Inc. (SANA) Presents At Citi's Biopharma Back To School Conference TranscriptSeptember 2, 2025 | seekingalpha.comSana Biotechnology Announces Public Offering PricingAugust 28, 2025 | theglobeandmail.comSana Biotechnology to Present at September 2025 Investor ConferencesAugust 26, 2025 | globenewswire.comDeutsche Bank AG Has $1.12 Million Stock Holdings in Sana Biotechnology, Inc. $SANAAugust 26, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSANA, IMVT, HCM, and OGN Company DescriptionsHUTCHMED NASDAQ:HCM$17.54 -0.39 (-2.18%) Closing price 04:00 PM EasternExtended Trading$17.55 +0.01 (+0.06%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.Immunovant NASDAQ:IMVT$15.53 -0.63 (-3.90%) Closing price 04:00 PM EasternExtended Trading$15.54 +0.01 (+0.06%) As of 04:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.Organon & Co. NYSE:OGN$10.38 -0.27 (-2.49%) Closing price 03:59 PM EasternExtended Trading$10.40 +0.02 (+0.14%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.Sana Biotechnology NASDAQ:SANA$3.23 +0.01 (+0.31%) Closing price 04:00 PM EasternExtended Trading$3.18 -0.04 (-1.39%) As of 04:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Royal Caribbean's 33% Dividend Hike Signals Deeper Growth MarketBeat Week in Review – 09/08 - 09/12 Adobe’s Rebound Has Room to Run: 25% Upside by Year-End Wall Street Eyes +30% Upside in Synopsys After Huge Earnings Fall Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
